KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortization of GoodwillCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in Working CapitalChange in Working CapitalDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDivestmentsExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationAmortization - GoodwillCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Teva Pharmaceutical Industries (TEVA) Short-Term Debt repayments (2020 - 2023)

Teva Pharmaceutical Industries filings provide 3 years of Short-Term Debt repayments readings, the most recent being $500.0 million for Q4 2023.

  • On a quarterly basis, Short-Term Debt repayments changed N/A to $500.0 million in Q4 2023 year-over-year; TTM through Dec 2024 was $700.0 million, a 41.67% decrease, with the full-year FY2023 number at $700.0 million, changed N/A from a year prior.
  • Short-Term Debt repayments hit $500.0 million in Q4 2023 for Teva Pharmaceutical Industries, up from $200.0 million in the prior quarter.
  • In the past five years, Short-Term Debt repayments ranged from a high of $500.0 million in Q4 2021 to a low of $200.0 million in Q3 2023.
  • Median Short-Term Debt repayments over the past 3 years was $471.5 million (2020), compared with a mean of $410.8 million.
  • The widest YoY moves for Short-Term Debt repayments: up 12.87% in 2021, down 12.87% in 2021.
  • Teva Pharmaceutical Industries' Short-Term Debt repayments stood at $443.0 million in 2020, then rose by 12.87% to $500.0 million in 2021, then changed by 0.0% to $500.0 million in 2023.
  • The last three reported values for Short-Term Debt repayments were $500.0 million (Q4 2023), $200.0 million (Q3 2023), and $500.0 million (Q4 2021) per Business Quant data.